ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
Summary
ChemT Biotechnology, an AI-driven company focused on biomanufacturing intelligence, has secured US\$5 million in funding over 18 months, comprising a US\$1 million angel investment and a US\$4 million seed round led by Wavemaker Ventures. This financing will expand ChemT's AI and experimental infrastructure, advance its AI-designed molecular products, and scale commercial partnerships. The company's core offering is CelMo™, an AI-driven Virtual Cell platform trained on billions to trillions of proprietary biological sequencing reads. CelMo™ simulates cell behavior under manufacturing conditions, identifying pathways to improve performance and designing small molecules to guide cell behavior. The platform has demonstrated a 50% increase in antibody output and a 40% reduction in production timelines in CHO cells. Additionally, its Chemplify™ product for T-cell manufacturing achieved 50% faster development, 3x scalability, 60% lower costs, and 10x higher cell expansion yield. ChemT plans to extend CelMo™ to stem cells, NK cells, and HEK cells.
Key takeaway
For Directors of Biomanufacturing seeking to overcome production bottlenecks, ChemT Biotechnology's AI-driven CelMo™ platform offers a validated approach. You can use its virtual cell simulations to precisely guide cell behavior. This could achieve significant gains, such as a 50% increase in antibody output or 60% lower T-cell manufacturing costs. Consider exploring this "intelligence layer" to enhance scalability and accelerate advanced medicine delivery, moving beyond automation-only solutions.
Key insights
AI-driven virtual cell platforms can precisely guide cell behavior to enhance biomanufacturing efficiency and scalability.
Principles
- Biomanufacturing bottlenecks stem from a lack of precise cellular manipulation.
- Integrating AI directly into manufacturing processes improves production reliability.
- Computational understanding of cellular networks enables targeted interventions.
Method
The CelMo™ platform simulates cell responses to manufacturing conditions and genetic changes, tracking internal biological processes to dynamically map cell states, then identifies pathways and designs small molecules to guide cell behavior.
In practice
- Achieve 50% higher antibody output and 40% faster timelines in CHO cells.
- Reduce T-cell manufacturing costs by 60% with 3x scalability.
Topics
- AI in Biomanufacturing
- CelMo™ Platform
- T-cell Manufacturing
- Cell Engineering
- Biotechnology Funding
- Advanced Medicines
Best for: Investor, Director of AI/ML, Domain Expert
Related on AIssential
Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.